

Creighton University

Award Year: 2013

Project Title: "PMP: Biologic Foundations for New Treatment Options"

Project Status: Closed

Update 1 (06-2015)

PMP patients have a high rate of mutations in the KRAS oncogene. Our research suggests that sustained signaling through the mutant KRAS protein (encoded by the KRAS oncogene) is necessary for maintenance of MUC2 (mucin 2, the predominant component of mucin in PMP) expression thereby linking signaling through KRAS oncoprotein to MUC2 expression. These results have implications for development of targeted treatment interventions for PMP.